The Korean journal of internal medicine

  • 제30권4호
  • /
  • Pages.423-433
  • /
  • 2015
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

A 2015 roadmap for the management of hepatitis C virus infections in Asia

  • Lim, Seng Gee (Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore) ;
  • Dan, Yock Young (Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore)
  • 투고 : 2015.05.27
  • 심사 : 2015.06.12
  • 발행 : 2015.07.01
⟨ 이전 논문 다음 논문 ⟩

초록

The prevalence of hepatitis C virus (HCV) in Asia is 0.5% to 4.7%, with three different genotypes predominating, depending on the geographic region: genotype 1b in East Asia, genotype 3 in South and Southeast Asia, and genotype 6 in Indochina. Official approval for direct-acting antiviral agents (DAAs) in Asia lags significantly behind that in the West, such that in most countries the mainstay of therapy is still pegylated interferon and ribavirin (PR). Because the interleukin-28B genetic variant, associated with a high sustained virologic response (SVR), is common in Asians, this treatment is still acceptable in Asian patients with HCV infections. A roadmap for HCV therapy that starts with PR and takes into account those DAAs already approved in some Asian countries can provide guidance as to the best strategies for management, particularly of genotype 1 and 3 infections, based on SVR rates. Sofosbuvir and PR are likely to be the initial therapies for genotype 1 and 3 disease, although in the former these drugs may be suboptimal in patients with cirrhosis (62% SVR) and the extension of treatment to 24 weeks may be required. For difficult to treat genotype 3 infections in treatment-experienced patients with cirrhosis, a combination of sofosbuvir and PR result in an 83% SVR and is, therefore, currently the optimal treatment regimen. Treatment failure is best avoided since data on rescue therapies for DAA failure are still incomplete.

키워드

참고문헌

  1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-115. https://doi.org/10.1111/j.1469-0691.2010.03432.x
  2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342. https://doi.org/10.1002/hep.26141
  3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128. https://doi.org/10.1016/S0140-6736(12)61728-0
  4. International Monetary Fund. Download entire World Economic Outlook database [Internet]. Washington (DC): International Monetary Fund, 2015 [cited 2015 Apr 22]. Available from: http://www.imf.org/external/pubs/ft/weo/2015/01/weodata/download.aspx.
  5. Institute for Health Metrics and Evaluation. Global burden of diseases, injuries and risk factors study operations manual [Internet]. Seattle (WA): Institute for Health Metrics and Evaluation, c2015 [cited 2015 Apr 23]. Available from: http://www.globalburden.org.
  6. Lim SG, Amarapurkar DN, Chan HL, et al. Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int 2015;9:43-51. https://doi.org/10.1007/s12072-014-9593-x
  7. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31 Suppl 2:61-80. https://doi.org/10.1111/j.1478-3231.2011.02540.x
  8. Umar M, Bushra HT, Ahmad M, et al. Hepatitis C in Pakistan: a review of available data. Hepat Mon 2010;10:205-214.
  9. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106:148-155. https://doi.org/10.1016/S0929-6646(09)60231-X
  10. Ampuero J, Romero-Gomez M, Reddy KR. Review article: HCV genotype 3: the new treatment challenge. Aliment Pharmacol Ther 2014;39:686-698. https://doi.org/10.1111/apt.12646
  11. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63:199-236. https://doi.org/10.1016/j.jhep.2015.03.025
  12. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis [Internet]. c2014 [cited 2015 May 22]. Available from: http://www.hcvguidelines.org.
  13. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-435. https://doi.org/10.1007/s12072-012-9342-y
  14. Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012;36:104-114. https://doi.org/10.1111/j.1365-2036.2012.05145.x
  15. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-1269. https://doi.org/10.1086/592579
  16. Liu CH, Liang CC, Liu CJ, et al. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther 2012;17:477-484.
  17. Sukeepaisarnjaroen W, Pham T, Tanwandee T, et al. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers. World J Gastroenterol 2015 Jan 8 [Epub].
  18. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(3 Suppl 1):112S-121S. https://doi.org/10.1002/hep.510260720
  19. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014;61:219-227. https://doi.org/10.1016/j.jhep.2014.04.004
  20. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887. https://doi.org/10.1056/NEJMoa1214853
  21. Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014;60(Suppl 1):220A.
  22. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597-1605. https://doi.org/10.1016/S0140-6736(14)61059-X
  23. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59:2083-2091. https://doi.org/10.1002/hep.27113
  24. Poole RM. Daclatasvir + asunaprevir: first global approval. Drugs 2014;74:1559-1571. https://doi.org/10.1007/s40265-014-0279-4
  25. Kosaka K, Imamura M, Hayes CN, et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat 2015;22:158-165. https://doi.org/10.1111/jvh.12271
  26. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221. https://doi.org/10.1056/NEJMoa1306218
  27. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 Phase 3 Study. Proceedings of the 50th annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna (AU). Geneva (CH): European Association for the Study of the Liver, 2015.
  28. Foster GR, McLauchlan J, Irving W, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. Proceedings of the 50th annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna (AU). Geneva (CH): European Association for the Study of the Liver, 2015.
  29. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008;28:397-404. https://doi.org/10.1111/j.1365-2036.2008.03763.x
  30. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;369:678-679. https://doi.org/10.1056/NEJMc1307641
  31. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001. https://doi.org/10.1056/NEJMoa1316145
  32. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877. https://doi.org/10.1056/NEJMoa1214854
  33. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015;61:769-775. https://doi.org/10.1002/hep.27567
  34. Cheinquer H, Shiffman ML, Zeuzem S, et al. The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study. Hepatology 2012;56(Suppl 1):156A.
  35. Shoeb D, Dearden J, Weatherall A, et al. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. J Hepatol 2014;60:699-705. https://doi.org/10.1016/j.jhep.2013.11.011
  36. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-1135. https://doi.org/10.1002/hep.27726
  37. Hezode C, de Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with hcv genotype 3 infection: interim analysis of a French multicenter compassionate use program. Proceedings of the 50th annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna (AU). Geneva (CH): European Association for the Study of the Liver, 2015.
  38. Nguyen NH, McCormack SA, Vutien P, et al. Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin. Intervirology 2015;58:27-34. https://doi.org/10.1159/000369097
  39. Wang X, Liu F, Wei F, Ren H, Hu H. Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis. PLoS One 2014;9:e100128. https://doi.org/10.1371/journal.pone.0100128
  40. Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology 2014;60(6 Suppl):1274A.
  41. Tarn YH, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health 2008;11 Suppl 1:S137-S155. https://doi.org/10.1111/j.1524-4733.2008.00378.x
  42. Hoofnagle JH, Sherker AH. Therapy for hepatitis C: the costs of success. N Engl J Med 2014;370:1552-1553. https://doi.org/10.1056/NEJMe1401508
  43. Gilead Sciences. Chronic hepatitis C treatment expansion: generic manufacturing for developing countries [Internet]. Foster City (CA): Gilead, c2009 [cited 2015 Apr 22]. Available from: http://www.gilead.com/-/media/Files/pdfs/other/HCVGenericAgreementFactSheet.pdf.
  44. Suthar AB, Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med 2015;12:e1001795. https://doi.org/10.1371/journal.pmed.1001795
  45. Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 2014;146:1145-1150.e4. https://doi.org/10.1053/j.gastro.2014.03.008
  46. Lim SG. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. World J Gastroenterol 2015;21:1972-1981. https://doi.org/10.3748/wjg.v21.i6.1972

피인용 문헌

  1. Cost‐effectiveness of strategy‐based approach to treatment of genotype 1 chronic hepatitis C vol.31, pp.9, 2015, https://doi.org/10.1111/jgh.13341
  2. Urgency to treat patients with chronic hepatitis C in Asia vol.32, pp.5, 2015, https://doi.org/10.1111/jgh.13709
  3. Daclatasvir/asunaprevir/beclabuvir, all‐oral, fixed‐dose combination for patients with chronic hepatitis C virus genotype 1 vol.32, pp.12, 2015, https://doi.org/10.1111/jgh.13796
  4. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis vol.5, pp.1, 2018, https://doi.org/10.1136/bmjgast-2018-000207
  5. Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection vol.2, pp.5, 2015, https://doi.org/10.1002/hep4.1177
  6. Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations vol.60, pp.1, 2019, https://doi.org/10.11622/smedj.2018078
  7. A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals? vol.14, pp.2, 2015, https://doi.org/10.1371/journal.pone.0211795
  8. A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants vol.12, pp.None, 2015, https://doi.org/10.2147/cpaa.s224662
  9. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study vol.37, pp.3, 2021, https://doi.org/10.1002/kjm2.12317